FindTrial
Sign In

To study the role of Quantitative Sensory Testing in detection of Diabetic Neuropathy.

The Role of Quantitative Sensory Testing in Asymptomatic Diabetic Neuropathy and its relationship with HbA1c.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2012/07/002834
Enrollment
86
Registered
2012-07-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diabetes

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18 and above. 2. Diabetic patients who underwent Quantitative Sensory Testing (QST).

Exclusion criteria

Exclusion criteria: 1. Patients with known vitamin B12 deficiency, chronic inflammatory polyneuropathy. 2. Patients taking neurotoxic drugs (cytotoxic drugs, isoniazid, metronidazole, chloramphenicol, nitrofurantoin, amiodarone, phenytoin, simvastatin). 3. Patients who present with heavy alcohol abuse (12), >=75 g daily. 4. Patients with known vasculitis. 5. Patients with known heavy metal poisoning. 6. Patients suffering from cancer or on chemotherapy. 7. Patients with severe chronic kidney disease based on clinical findings.

Design outcomes

Primary

MeasureTime frame
Role and importance of QST in diagnosis of Diabetic Neuropathy and its relationship with glycated hemoglobin (HbA1c).Timepoint: Visit and Follow-up—

Secondary

MeasureTime frame
NATimepoint: NA—

Countries

India

Contacts

Public ContactDr Sujeet Jha

Max Healthcare

sakshi.popli17@gmail.com9999478854

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026